Pioglitazone and Bladder cancer: is the FAERS signal real?
Pioglitazone ↔ Bladder cancer
Reporting over time (stimulated-reporting check)
Reporting spiked in 2011, 2012, 2013, 2015, 2016, 2017, 2018, 2019, 2020 — 75% of all 8,736 reports arrived in two years (2015–2016). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Pioglitazone, a thiazolidinedione for type 2 diabetes, was flagged for a possible bladder-cancer risk by a French national cohort in 2011, which led France to suspend the drug and prompted the FDA and EMA to add warnings and restrict its use (FDA label warning, 2011). Yet the picture has not resolved cleanly: several large subsequent observational studies and pooled analyses found little to no increase in bladder-cancer risk, and some of the FAERS over-reporting almost certainly reflects intensified bladder/prostate surveillance in this population plus the regulatory scare itself driving reporting. The honest grade is "contested," not "established" — a labeled caution resting on genuinely disagreeing evidence.
Regulatory basis: FDA drug safety communication and label change (2011); ANSM (France) suspension (2011); EMA review. The epidemiological evidence is mixed, with later large studies finding little to no elevated risk.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | Plausible (years of exposure precede diagnosis), but cancer latency makes it hard to pin down |
| Strength | met | PRR 84 — but very likely inflated by reporting and surveillance bias |
| Consistency | not established | Large studies genuinely disagree on whether risk is elevated at all |
| Specificity | partial | Bladder is a specific organ, but this population is heavily screened for it |
| Biological gradient | partial | Some studies suggest a duration/dose trend; others find none |
| Plausibility | partial | Rodent urothelial tumors exist; human relevance is uncertain |
| Coherence | not established | Does not cohere into a decisive pattern either way |
| Experiment | not established | No randomized trial was designed to test this outcome |
| Analogy | partial | A few other drug classes carry debated bladder-cancer signals |
This page's own qualitative read, not an automated/citation-gated assessment.